Janus Henderson Group PLC Acquires New Stake in UroGen Pharma Ltd. (NASDAQ:URGN)

Janus Henderson Group PLC bought a new position in shares of UroGen Pharma Ltd. (NASDAQ:URGN) in the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $149,000. Janus Henderson Group PLC owned approximately 0.06% of UroGen Pharma at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in URGN. Acorn Capital Advisors LLC acquired a new stake in UroGen Pharma in the 4th quarter valued at approximately $16,149,000. Nantahala Capital Management LLC acquired a new stake in shares of UroGen Pharma in the fourth quarter valued at approximately $14,608,000. Rosalind Advisors Inc. bought a new stake in shares of UroGen Pharma in the fourth quarter worth $9,266,000. Price T Rowe Associates Inc. MD boosted its holdings in UroGen Pharma by 2,968.7% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 393,984 shares of the company’s stock worth $4,197,000 after purchasing an additional 381,145 shares during the last quarter. Finally, Cantor Fitzgerald L. P. acquired a new position in UroGen Pharma during the fourth quarter worth $3,787,000. Institutional investors own 91.29% of the company’s stock.

UroGen Pharma Price Performance

NASDAQ:URGN opened at $4.19 on Monday. UroGen Pharma Ltd. has a 12-month low of $3.42 and a 12-month high of $20.70. The firm has a market capitalization of $193.19 million, a price-to-earnings ratio of -1.33 and a beta of 0.66. The stock’s 50 day moving average price is $10.03 and its two-hundred day moving average price is $10.65. The company has a quick ratio of 8.77, a current ratio of 9.00 and a debt-to-equity ratio of 4.77.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The business had revenue of $20.25 million for the quarter, compared to analysts’ expectations of $22.71 million. On average, analysts anticipate that UroGen Pharma Ltd. will post -3.12 earnings per share for the current year.

Wall Street Analyst Weigh In

Several brokerages have commented on URGN. D. Boral Capital reissued a “buy” rating and set a $25.00 price target on shares of UroGen Pharma in a research report on Thursday, May 8th. Scotiabank started coverage on UroGen Pharma in a report on Wednesday, April 16th. They set a “sector outperform” rating and a $23.00 target price on the stock. The Goldman Sachs Group decreased their price target on UroGen Pharma from $16.00 to $3.00 and set a “neutral” rating for the company in a research note on Thursday. HC Wainwright cut UroGen Pharma from a “buy” rating to a “neutral” rating in a research note on Thursday. Finally, LADENBURG THALM/SH SH assumed coverage on UroGen Pharma in a report on Wednesday, February 19th. They issued a “buy” rating and a $31.00 price objective for the company. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $27.43.

About UroGen Pharma

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.